Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Ligelizumab Maintains Urticaria Control For Up to 1 Year

Key clinical point: The anti-IgE monoclonal antibody controlled hives and other symptoms well for up to a year.

Major finding: About 75% of the cohort experienced complete disease control at least once during the study.

Study details: The extension study comprised 96 patients treated with ligelizumab for 12 weeks in a phase 2 study.

Disclosures: Dr. Baker is a clinical trials investigator for Novartis, which is developing ligelizumab.

Citation:

Baker D et al. AAD 2019, Session S034.